UK pharma opposes proposals to base off-label prescribing decisions on cost
This article was originally published in SRA
A proposal by the UK's General Medical Council to allow doctors to prescribe unlicensed or "off-label" medicines on the basis that they are less expensive than licensed medicines meeting the same clinical need has been criticised by the pharmaceutical industry, which says the practice will put patient safety at risk and undermine the medicines regulatory process1-4.
You may also be interested in...
The Canadian medtech regulator has recommended updating its list of recognized medical device standards that manufacturers can rely on to demonstrate compliance with local safety, effectiveness and labeling requirements.
Reports from Norway about deaths in very frail, elderly patients soon after receiving Pfizer/BioNTech’s COVID-19 jab have drawn regulatory scrutiny. While the European Medicines Agency has launched an investigation, Australia is examining the need for specific warnings about risks of vaccination in the very frail elderly or terminally ill patients.
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.